Epirubitec
Composition
Epirubicin Hydrochloride10mg / 50mg Vials
Pharmaceutical form
VialsTherapeutic Indications
Breast CancerOvarian Cancer
Gastric Cancer
Lung Cancer
Lymphomas
Bladder Cancer
Posology and method of administration
EPIRUBITEC is given in repeated 3 to 4 week cycles.The total dose of EPIRUBITEC may be given on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle. The recommended dosages of EPIRUBITEC are as follows:
Starting Doses
: The recommended starting dose of EPIRUBITEC is 100 to 120 mg/m2. The following regimens were used in the trials supporting use of EPIRUBITEC as a component of adjuvant therapy in patients with axillary-node positive breast cancer;
CEF-120
: Cyclophosphamide-75 mg/m2 PO Day 1-14 EPIRUBITEC- 60 mg/m2 IV Day 1, 8 5-Fluorouracil -500 mg/m2 IV Day 1, 8 Repeated every 28 days for 6 cycles
FEC-100
: 5-Fluorouracil- 500 mg/m2, EPIRUBITEC- 100 mg/m2, Cyclophosphamide- 500 mg/m2
Interaction with other pharmaceuticals
Not AvailablePregnancy and lactation
Not AvailableEffects on abilities
Not AvailableOverdose
Not AvailablePharmacological Properties
Not AvailableExcipients
Not AvailableShelf life
Not AvailableStorage
Not AvailablePackaging
1 Vial of 10mg1 Vial of 50mg